NCT01728402 2026-02-17
Pathogenesis of Hematologic Malignancies
OHSU Knight Cancer Institute
Enrolling by invitation
Clinical Trials
8 trialsNCT07383298 2026-02-03
Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
Peking University People's Hospital
Enrolling by invitation
NCT00923442 2026-01-05
Biology Studies of Hematologic Cancers
National Institutes of Health Clinical Center (CC)
Enrolling by invitation
NCT04093570 2025-10-31
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Taiho Oncology, Inc.
Phase 2 Enrolling by invitation
NCT06788509 2025-10-10
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
NCT02646839 2025-05-04
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
Pediatric Transplantation & Cellular Therapy Consortium
Phase 2 Enrolling by invitation
NCT05674539 2025-02-10
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Enrolling by invitation
NCT06646978 2024-10-17
K2SPIRIT
Poitiers University Hospital
Enrolling by invitation